Fisher Scientific International
This article was originally published in The Gray Sheet
Executive Summary
Files registration statement with the Securities and Exchange Commission relating to a proposed offering of $125 mil. in step-up convertible subordinated notes due in 2003. The research and testing product manufacturer plans to use $40 mil. of anticipated proceeds to repay outstanding debt related to its Dec. 31 acquisition of the Hamilton Division of Hamilton Industries; the division manufactures laboratory systems and equipment. The balance of proceeds will be used for general corporate purposes, "including working capital, capital expenditures and potential acquisitions." Underwriting the offering are The First Boston Co.; BT Securities; Donaldson, Lufkin & Jenrette; Lazard Freres; and Smith Barney, Harris Upham.
You may also be interested in...
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.